The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness

BACKGROUND: First-generation integrase strand-transfer inhibitors (INSTIs), such as raltegravir (RAL) and elvitegravir (EVG), have been clinically proven to be effective antiretrovirals for the treatment of HIV-positive patients. However, their relatively low genetic barrier for resistance makes the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wares, Melissa, Mesplède, Thibault, Quashie, Peter K, Osman, Nathan, Han, Yingshan, Wainberg, Mark A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898230/
https://www.ncbi.nlm.nih.gov/pubmed/24433497
http://dx.doi.org/10.1186/1742-4690-11-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898230/
https://www.ncbi.nlm.nih.gov/pubmed/24433497
http://dx.doi.org/10.1186/1742-4690-11-7

Ejemplares similares